Viking Therapeutics Inc (NASDAQ:VKTX)’s share price gapped down prior to trading on Thursday . The stock had previously closed at $14.33, but opened at $14.04. Viking Therapeutics shares last traded at $13.14, with a volume of 4931652 shares changing hands.
Several equities analysts have weighed in on VKTX shares. BidaskClub cut Viking Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, September 7th. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Viking Therapeutics in a report on Friday, August 10th. William Blair reaffirmed an “outperform” rating on shares of Viking Therapeutics in a report on Friday, August 10th. Maxim Group reaffirmed a “buy” rating and issued a $28.00 price objective (up from $14.00) on shares of Viking Therapeutics in a report on Tuesday, September 18th. Finally, Raymond James reaffirmed an “outperform” rating and issued a $43.00 price objective (up from $15.00) on shares of Viking Therapeutics in a report on Tuesday, September 18th. One research analyst has rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $28.17.
The firm has a market cap of $833.44 million, a price-to-earnings ratio of -16.23 and a beta of 2.92.
In other news, major shareholder Ligand Pharmaceuticals Inc sold 262,881 shares of Viking Therapeutics stock in a transaction on Tuesday, September 25th. The stock was sold at an average price of $19.15, for a total value of $5,034,171.15. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 3.90% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the company. First Mercantile Trust Co. bought a new position in shares of Viking Therapeutics in the 3rd quarter valued at $131,000. Janney Montgomery Scott LLC bought a new position in shares of Viking Therapeutics in the 2nd quarter valued at $114,000. Strs Ohio bought a new position in shares of Viking Therapeutics in the 2nd quarter valued at $120,000. Cubist Systematic Strategies LLC bought a new position in shares of Viking Therapeutics in the 2nd quarter valued at $129,000. Finally, State Board of Administration of Florida Retirement System bought a new position in shares of Viking Therapeutics in the 2nd quarter valued at $144,000. Institutional investors own 53.56% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Viking Therapeutics (VKTX) Shares Gap Down to $14.04” was originally reported by WKRB News and is the sole property of of WKRB News. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.wkrb13.com/2018/11/09/viking-therapeutics-vktx-shares-gap-down-to-14-04.html.
Viking Therapeutics Company Profile (NASDAQ:VKTX)
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures.
Further Reading: Understanding Market Liquidity
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.